Reduced amyloid‐β degradation in early Alzheimer's disease but not in the APP swe PS 1dE9 and 3xTg‐AD mouse models
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary: Alzheimer's disease (AD) is hallmarked by amyloid‐β (Aβ) peptides accumulation and aggregation in extracellular plaques, preceded by intracellular accumulation. We examined whether intracellular Aβ can be cleared by cytosolic peptidases and whether this capacity is affected during progression of sporadic AD (s AD) in humans and in the commonly used APP swePS1dE9 and 3xTg‐AD mouse models. A quenched Aβ peptide that becomes fluorescent upon degradation was used to screen for Aβ‐degrading cytoplasmic peptidases cleaving the aggregation‐prone KLVFF region of the peptide. In addition, this quenched peptide was used to analyze Aβ‐degrading capacity in the hippocampus of s AD patients with different Braak stages as well as APP swePS1dE9 and 3xTg‐AD mice. Insulin‐degrading enzyme (IDE) was found to be the main peptidase that degrades cytoplasmic, monomeric Aβ. Oligomerization of Aβ prevents its clearance by IDE. Intriguingly, the Aβ‐degrading capacity decreases already during the earliest Braak stages of s AD, and this decline correlates with IDE protein levels, but not with m RNA levels. This suggests that decreased IDE levels could contribute to early s AD. In contrast to the human data, the commonly used APP swePS1dE9 and 3xTg‐AD mouse models do not show altered Aβ degradation and IDE levels with AD progression, raising doubts whether mouse models that overproduce Aβ peptides are representative for human s AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“According to the amyloid-cascade hypothesis, Ab accumulation in the brain drives further AD pathogenesis, such as tau aggregation, synaptic dysfunction, and eventually neuronal death (Hardy & Allsop, 1991; Murrell et al., 1991; Hardy & Selkoe, 2002; Querfurth & LaFerla, 2010; Tam & Pasternak, 2012).”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 2×
“Here, overproduction of the Ab peptide is the primary cause for AD, in contrast to human sAD where decreased clearance of Ab seems to be the primary mechanism underlying the development of the disease, also confirming previous data (Dorfman et al., 2010; Mawuenyega et al., 2010).”
BackgroundResultAmyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“While the rare autosomal dominant familial AD (fAD) is mostly due to overproduction of Ab (Bertram et al., 2010; O’Brien & Wong, 2011) or enhancing Ab protofibril formation (Nilsberth et al., 2001), far more common is late-onset sporadic AD (sAD), thought to be caused by decreased clearance of the…”
BackgroundIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 5×
“Double APPswePS1dE9 transgenic mice expressed chimeric mouse/ human APP containing the K595N/M596L Swedish mutation and human PS1 variant carrying the exon 9 deletion both driven by mouse prion promoter elements, directing the expression to neurons (Jankowsky et al., 2004).”
BackgroundInfluentialThe 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 2×
“, 2010; O'Brien & Wong, 2011) or enhancing Ab protofibril formation (Nilsberth et al., 2001), far more common is late-onset sporadic AD (sAD), thought to be caused by decreased clearance of the Aβ peptide (Dorfman et al.”
BackgroundAmyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 4×
“In addition, increased endogenous Ab levels are found in both hippocampal tissue of AD patients (Matsui et al., 2007), as well as in the APPswePS1dE9 and 3xTg-AD mouse models (Oddo et al., 2003a; Kamphuis et al., 2012b).”
BackgroundInfluentialArrest of -Amyloid Fibril Formation by a Pentapeptide Ligand
Tjernberg, L. O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A. R., Thyberg, J., Terenius, L., & Nordstedt, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8545 · Cited by 963
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Cited by
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185
Stargardt, A., Swaab, D. F., & Bossers, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.014 · Cited by 109
Self-citationVitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Adalier, N., & Parker, H. (2016) · Antioxidants · doi:10.3390/antiox5040040 · Cited by 40
Lian, B., Liu, M., Lan, Z., Sun, T., Meng, Z., Chang, Q., Liu, Z., Zhang, J., & Zhao, C. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112503 · Cited by 19
Lauer, A. A., Mett, J., Janitschke, D., Thiel, A., Stahlmann, C. P., Bachmann, C. M., Ritzmann, F., Schrul, B., Müller, U. C., Stein, R., et al. (2020) · Aging Cell · doi:10.1111/acel.13264 · Cited by 15
“Error bars represent the standard error of the mean and significance was set at *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 degraded among others by IDE or NEP, which play also an important role in intracellular Aβ-degradation (Iwata et al., 2001; Stargardt et al., 2013).”
BackgroundMethodInfluential
Metadata
- Authors
- Stargardt, A., Gillis, J., Kamphuis, W., Wiemhoefer, A., Kooijman, L., Raspe, M., Benckhuijsen, W., Drijfhout, J. W., M. Hol, E., & Reits, E.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2013-04-23
- Volume
- 12
- Issue
- 3
- Pages
- 499-507
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2026399828
- Cited by
- 67
- References
- 16
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.